Collaborative Review – Bladder CancerRecurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
Introduction
The global incidence of urinary bladder cancer (BCa) was approximately 357 000 cases in 2002 [1]. The vast majority of these cancers are urothelial carcinomas, and it is a disease of the elderly population. The highest incidence rates are observed in North America and Western Europe [1], [2], while the lowest incidence rates are found in the Asian countries (China, Japan, Korea) and central Africa [1], [3]. Variation in registration of pTa (low-grade) tumours may partly be the cause of these differences [4]. Apart from age, the most important risk factors are smoking, occupational exposure, certain medical treatments, and genetic predisposition [4], [5], [6], [7], [8], [9], [10], [11].
Table 1 shows the worldwide incidence, mortality, and prevalence of BCa for males and females and for more- and less-developed countries. Globally, BCa is the 7th most common cancer in men and the 17th in women [1]. In the United States, it is the 4th most common cancer in men and the 10th in women [2]. Most (75–85%) BCa incidences are non–muscle invasive at first diagnosis (pTa, pT1, carcinoma in situ [CIS]) [12]. In non–muscle-invasive bladder cancer (NMIBC), approximately 70% of patients present as pTa, 20% as pT1, and 10% as CIS lesions [13]. Generally, the prognosis of NMIBC is good, although 30–80% of cases will recur and 1–45% of cases will progress to muscle invasion within 5 yr [12], [13], [14], [15], [16]. Consequently, NMIBC is a chronic disease with varying oncologic outcomes requiring frequent follow-up and repeated treatments, making the cost per patient from diagnosis to death the highest of all cancers [17], [18]. At any point in time, 2.7 million people in the world have a history of BCa [19].
Section snippets
Evidence acquisition
A literature search in English was performed using PubMed and the guidelines of the European Association of Urology (EAU) and the American Urological Association (AUA). Relevant papers on epidemiology, recurrence, progression, and management of NMIBC were selected. Next to clinical and pathologic variables for recurrence and progression, special attention has been paid to fluorescence cystoscopy (FC), the new World Health Organisation (WHO) 2004 classification system for grading, and the role
Clinical and pathologic factors of recurrence
Clinical and pathologic factors for NMIBC recurrence have been studied extensively over the years [15], [20], [21], [22], [23], [24], [25], [26]. Although studies vary in the number of patients included, duration of follow-up, variables analysed, and statistical analysis, the most important variables for prediction of recurrence in patients with NMIBC are multiplicity, prior recurrence rate, and tumour size [15], [20], [21], [22], [23], [24], [25], [26]. Sylvester reviewed potential prognostic
Conclusions
NMIBC is a frequent and heterogeneous disease with varying oncologic outcomes. FC is a valuable add-on to WLC, as FC allows a more complete TUR, resulting in lower recurrence rates. It is not clear yet whether FC also results in lower progression rates. Multiplicity, tumour size, and prior recurrence rate are the most important variables for recurrence. Grade, stage, and CIS are the most important variables for progression. The new WHO 2004 classification system for grade precludes a one-on-one
References (141)
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer...
- et al.
Cancer statistics, 2008
CA Cancer J Clin
(2008) - et al.
Epidemiology, staging, grading, and risk stratification of bladder cancer
Eur Urol Suppl
(2008) - et al.
Epidemiology and genetic susceptibility to bladder cancer
BJU Int
(2008) - et al.
The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies
Cancer
(2000) - et al.
Epidemiology of urinary bladder cancer: from tumor development to patient's death
World J Urol
(2007) - et al.
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer
Nat Genet
(2008) - et al.
Familial aggregation of urothelial cell carcinoma
Int J Cancer
(2002) - et al.
Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study
Int J Cancer
(1995) - et al.
Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study
J Urol
(2008)
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses
Lancet
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
Eur Urol
Bladder cancer: epidemiology, staging and grading, and diagnosis
Urology
The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group
Br J Cancer
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
Eur Urol
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
J Urol
The health economics of bladder cancer
Pharmacoeconomics
Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis
Med Care
The present and future burden of urinary bladder cancer in the world
World J Urol
Prognostic factors in patients with non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials
Eur Urol
Factors affecting recurrence and progression in superficial bladder tumours
Eur J Cancer
Prognostic factors in non–muscle-invasive bladder tumors: I. Clinical prognostic factors: a review of the experience of the EORTC Genito-Urinary group II: biologic prognostic markers
Eur Urol Suppl
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence
J Urol
Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression
BJU Int
Multivariate analysis of the prognostic factors of primary superficial bladder cancer
J Urol
Natural history, recurrence and progression in superficial bladder cancer
TSW Urology
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
J Urol
Nomograms for bladder cancer
Eur Urol
Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study
J Urol
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies
Eur Urol
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer
J Urol
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study
J Urol
The past, present, and future of cystoscopy: the fusion of cystoscopy and novel imaging technology
BJU Int
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy
J Urol
Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder
Urology
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study
J Urol
Clinically relevant risk of reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid induced fluorescence diagnosis: 8-years results of prospective randomized study
Urology
Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?
BJU Int
Hexylaminolaevulinate ‘blue light’ fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology
BJU Int
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis
Eur Urol
Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study
BJU Int
Prognostic markers in bladder cancer: a contemporary review of the literature
J Urol
Genomics: a preview of genomic medicine
BJU Int
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese
Carcinogenesis
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome
J Clin Oncol
Two molecular pathways to transitional cell carcinoma of the bladder
Cancer Res
Prediction of progression of non–muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study
Eur Urol
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas
J Clin Oncol
Analysis of the performance of pathologists in the grading of bladder tumors
Hum Pathol
Cited by (589)
A first-in-class β-glucuronidase responsive conjugate for selective dual targeted and photodynamic therapy of bladder cancer
2024, European Journal of Medicinal ChemistryDoes the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor?
2024, Photodiagnosis and Photodynamic TherapyPreoperative urine sediment chromosomal instability level predicts urothelial cancer prognosis
2023, Urologic Oncology: Seminars and Original InvestigationsCDK2 and CDK4 targeted liensinine inhibits the growth of bladder cancer T24 cells
2023, Chemico-Biological Interactions